Search Results

Business

Medicago announces the appointment of Toshifumi Tada as President and CEO

Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, announced the appointment of Toshifumi Tada as President and chief executive officer, effective on May 1, 2022.

April 28, 2022

·

2 min read

Drug Development

Clinical Catch-Up: Pfizer’s Paxlovid Gaff, a Win for Medicago-GSK’s Vaccine

Pfizer’s Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.

May 6, 2022

·

9 min read

·

Mark Terry

Policy

Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age

Health Canada authorized Medicago’s Covifenz COVID-19 vaccine for the prevention of COVID-19 in adults 18 to 64 years of age.

February 24, 2022

·

2 min read

Drug Development

Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory review by Health Canada as part of the New Drug Submission for COVID (NDS-CV) rolling review for Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant.

December 16, 2021

·

3 min read

Drug Development

Medicago announces publication of Phase 3 COVID-19 vaccine study results in New England Journal of Medicine

Medicago today announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted), in the New England Journal of Medicine (NEJM).

May 5, 2022

·

2 min read

Job Trends

Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).

February 24, 2022

·

5 min read

Job Trends

Medicago and GSK announce the approval by Health Canada of COVIFENZ, an Adjuvanted Plant-Based COVID-19 Vaccine

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).

February 24, 2022

·

4 min read

Drug Development

Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate

Medicago, today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

December 7, 2021

·

7 min read

Pavlo Gonchar/SOPA Images/LightRocket via Getty Im

Drug Development

Medicago’s Plant-Based Vaccine Combined with GSK’s Adjuvant Tech Shines in Phase II

Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.

May 18, 2021

·

2 min read

·

Alex Keown

Drug Development

Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago’s plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK’s pandemic adjuvant.

May 18, 2021

·

5 min read